Loss-of-function mutations in Lysine Methyltransferase 2D (KMT2D) were found to potentiate anti-PD1 checkpoint immunotherapy by enhancing immune infiltration in the tumor microenvironment. This evidence concerns the gene KMT2D and neoplasm.